June 5, 2024
What We Do The Division of Applied Regulatory Science (DARS) moves new science into the FDA regulatory process and addresses emergent regulatory and public health questions. […]
June 5, 2024
Now that semaglutide (Wegovy), tirzepatide (Zepbound), and other injectables have created an insatiable market for weight loss drugs, biotech and pharmaceutical companies are roaring ahead with […]
June 5, 2024
Despite overall declines in cancer incidence and mortality, population growth and aging are predicted to drive an increase in the absolute number of people receiving a […]
June 5, 2024
A US Food and Drug Administration (FDA) expert panel has found that the benefits of the psychedelic midomafetamine (MDMA) in combination with psychological intervention for the […]
June 5, 2024
NASHVILLE, Tennessee — Interventions that stimulate the reward system may be the most effective treatment for fatigue directly related to multiple sclerosis (MS), experts said. Here […]
June 5, 2024
Immediate Office (IO) Iilun C. Murphy, M.D., Director, Office of Generic Drugs (OGD) Darby Kozak, PhD, Deputy Director Kendra Stewart, R.Ph., Pharm.D., Deputy Director for Operations […]
June 5, 2024
TOPLINE: A study found that higher insulin sensitivity is associated with a decrease in lean mass loss during weight loss. METHODOLOGY: Researchers conducted a 16-week controlled […]
June 5, 2024
Exercise interventions are recommended to help prevent falls and fall-related morbidity in community-dwelling adults aged 65 years and older who are at increased risk of falls, […]
June 5, 2024
Socioeconomic factors were associated with greater disease severity at the time of initial presentation in adults with sarcoidosis, based on a new study of more than […]